Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q2 2026 · $184.6MThe company’s own SEC segment disclosure.
- Liver Product$148.0M80%
- Heart Product$33.4M18%
- Lung Product$2.3M1%
- Service Unrelated To OCS Transplant$1.0M1%
TransMedics Group, Inc. (TMDX) reported revenue of $174M in Q1 2026 (quarter ended March 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $7.3M (4.2% of revenue). For the full year FY2025, revenue was $605M (+37% year on year) and net income $190M. Its largest product in 2026-Q2 was Liver Product at $148M, 80% of the disclosed total, just ahead of Heart Product at 18%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.